Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
Büyüközkan, Mustafa , Doraiswamy, P. Murali , Wu, Tong , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Krumsiek, Jan, Arnold, Matthias , Nho, Kwangsik T. , Guðnason, Vilmundur , Launer, Lenore J. , Wang‐Sattler, Rui , Adamski, Jerzy , Bennett, David A. , Saykin, Andrew J. , Peters, Annette , Suhre, Karsten , Kaddurah‐Daouk, Rima , Kastenmüller, Gabi

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.072776 Get It

AbstractBackgroundBrain glucose hypometabolism is among the earliest pathogenic changes in Alzheimer’s disease (AD). This metabolic dysfunction points to the personal bioenergetic capacity, defined as the ability to maintain energy homeostasis under all circumstances including deregulated glucose uptake, as a potential source of resilience to the disease. Fasting blood acylcarnitine profiles are a central readout for this capacity in the absence of dietary glucose and capture the activity and efficiency of glucose‐independent routes of mitochondrial energy metabolism.MethodWe used fasting serum acylcarnitine profiles of 1,531 participants (465 with normal cognition, 762 with mild cognitive impairment, and 304 with clinical AD) from the AD Neuroimaging Initiative to perform unsupervised subgroup identification using hierarchical clustering. Identified subgroups were investigated for differences in A/T/N biomarker profiles and cognitive status. The contributions of genetic and potentially modifiable factors defining the subgroups were quantified using analysis of explained variance. The influence of the strongest determining factors on longitudinal cognitive trajectories was estimated using linear mixed‐effects models and gene‐by‐environment interaction analysis.ResultWe found several bioenergetically distinct subgroups with significant differences in AD biomarker profiles and cognitive function. The strongest genetic contribution to this bioenergetic endophenotype seems to be specifically linked to succinylcarnitine metabolism and significantly modulates the rate of future cognitive decline. In contrast, potentially modifiable sustainment of beta‐oxidation efficiency seems to decelerate bioenergetic aging, thus creating a bioenergetic reserve that delays progression of cognitive decline. Using gene‐by‐environment interaction analysis, we demonstrate that this molecular framework identifies a subgroup of individuals that is likely to benefit significantly from personalized therapeutic, dietary or lifestyle interventions tailored to increase resilience against bioenergetic disturbances in AD.ConclusionOur study reports on a set of genetic and metabolic markers that define bioenergetically distinct subgroups with significant differences on the AD biomarker and cognitive level. Longitudinal data suggest that targeting the modifiable fraction of this endophenotype might be a promising strategy to slow down disease progression in individuals with specific allelic configurations.
DNA methylation clustered by predicted chromatin state reveals distinct association patterns with neuropathologic and biochemical measures in the AD brain
Oatman, Stephanie R., Quicksall, Zachary , Reddy, Joseph S. , Carrasquillo, Minerva M. , Wang, Xue , Nguyen, Thuy , Malphrus, Kimberly G., Martens, Yuka A. , DeTure, Michael , Kanekiyo, Takahisa , Allen, Mariet , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Liu, Chia‐Chen , Yamazaki, Yu , Heckman, Michael G. , Zhao, Na , Murray, Melissa E. , Bu, Guojun , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.072470 Get It

AbstractBackgroundAlzheimer’s disease (AD) is neuropathologically characterized by amyloid‐β (Aβ) plaques and tau neurofibrillary tangles often quantified by Thal phase and Braak stage, respectively. Aβ also frequently deposits in the cerebrovasculature with severity categorized by a cerebral amyloid angiopathy (CAA) score. These and related measures often show high variability within AD suggesting distinct underlying mechanisms, the identification of which may reveal important biological insights into AD pathophysiology. We hypothesize that, within the AD brain, neuropathology and levels of core AD‐related proteins are influenced by variations in DNA methylation (DNAm). To test this, we performed epigenome‐wide association studies (EWAS) using DNAm clusters from the temporal cortex (TCX) and cerebellum (CER) with AD‐related neuropathologic measures (Braak, Thal, and CAA) and brain biochemical levels of five proteins (apoE, Aβ40, Aβ42, tau, and p‐tau).MethodsDNAm from neuropathologically‐confirmed AD cases available through the Mayo Clinic brain bank was measured by reduced representation bisulfite sequencing (RRBS) from 471 brain samples, 200 of which had both TCX and CER measures. Neuropathology was scored by an experienced neuropathologist. TCX levels of five AD‐related proteins from three tissue fractions (buffer‐, detergent‐, and in‐soluble) were measured by ELISA (Liu 2020). CpG methylation (CpGm) was binned by a 15‐state chromatin model (Kundaje 2015) and averaged. Averaged CpGm clusters were tested for their association with each endophenotype through multi‐variable linear regression. The influence of CpGm clusters on expression levels of nearby genes was also investigated through multi‐variable regression.ResultsOur innovative binning method demonstrated expected and biologically relevant CpGm patterns. We identified multiple epigenome‐wide significant CpGm clusters unique to each AD‐related endophenotype and brain region. Comparisons between the TCX and CER further revealed brain region‐specific enrichment of distinct CpGm clusters. Significant CpGm clusters were further characterized by their influence on gene expression.ConclusionsAlthough all neuropathologic and biochemical endophenotypes tested are core to AD pathophysiology, our results suggest each has a distinct epigenetic architecture underlying their variability in the AD brain. By discovering brain region‐specific DNAm changes that contribute to each neuropathologic or biochemical outcome, we can identify core components of complex mechanisms that individually and jointly contribute to AD.
Medial Collateral Ligament Reconstruction of the Knee: The Modified Marx Technique With Adjustable‐Loop Femoral Fixation and Posteromedial Corner Plication
Boos, Alexander M. , Hevesi, Mario , Wang, Allen S. , Fiegen, Anthony P. , Levy, Bruce A. , Wang, Allen , Boos, Alexander , Hevesi, Mario

Mayo Clinic

Arthroscopy Techniques | December 25, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1016/j.eats.2023.09.007 | PMID 38312880 Get It

Abstract The medial collateral ligament serves as the primary stabilizer to valgus stress on the medial side of the knee and is the most commonly injured ligament in the knee. Medial collateral ligament reconstruction can provide improved stability and clinical outcomes for patients. Advancements in techniques, including the use of an adjustable‐length‐loop suspensory fixation device through a longitudinal incision, have been introduced in recent years. The purpose of this Technical Note and video is to provide a minimally invasive method for medial collateral ligament reconstruction with adjustable‐loop femoral fixation and posteromedial corner plication. Technique Video video See video under supplementary data.
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic Catastrophe
Rachamala, Hari K., Dutta, Shamit K., Wang, Enfeng , Angom, Ramcharan S, Nakka, Naga M, Kumar Dutta, Shamit, Madamsetty, Vijay Sagar , Angom, Ramcharan Singh , Nakka, Naga Malleswara Rao , Mukhopadhyay, Debabrata , Pal, Krishnendu

Mayo Clinic

No container title available | December 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3770403/v1 | PMID 38196607 Get It

Abstract Background Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiotherapy (SABR) have led to better outcomes and reduced treatment-related toxicities, sparking renewed interest in using RT to treat RCC. Moreover, numerous studies have revealed that certain therapeutic agents including chemotherapies can increase the sensitivity of tumors to RT, leading to a growing interest in combining these treatments. Here, we developed a rational combination of two radiosensitizers in a tumor-targeted liposomal formulation for augmenting RT in RCC. The objective of this study is to assess the efficacy of a tumor-targeted liposomal formulation combining the mTOR inhibitor everolimus (E) with the survivin inhibitor YM155 (Y) in enhancing the sensitivity of RCC tumors to radiation. Experimental Design: We slightly modified our previously published tumor-targeted liposomal formulation to develop a rational combination of E and Y in a single liposomal formulation (EY-L) and assessed its efficacy in RCC cell lines in vitro and in RCC tumors in vivo. We further investigated how well EY-L sensitizes RCC cell lines and tumors toward radiation and explored the underlying mechanism of radiosensitization. Results EY-L outperformed the corresponding single drug-loaded formulations E-L and Y-L in terms of containing primary tumor growth and improving survival in an immunocompetent syngeneic mouse model of RCC. EY-L also exhibited significantly higher sensitization of RCC cells towards radiation in vitro than E-L and Y-L. Additionally, EY-L sensitized RCC tumors towards radiation therapy in xenograft and murine RCC models. EY-L mediated induction of mitotic catastrophe via downregulation of multiple cell cycle checkpoints and DNA damage repair pathways could be responsible for the augmentation of radiation therapy. Conclusion Taken together, our study demonstrated the efficacy of a strategic combination therapy in sensitizing RCC to radiation therapy via inhibition of DNA damage repair and a substantial increase in mitotic catastrophe. This combination therapy may find its use in the augmentation of radiation therapy during the treatment of RCC patients.
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling
Hage, Stephanie , Kinkade, Serena , Flemming, Kelly D. , Kim, Helen , Torbey, Michel , Huang, Judy , Huston, John , Shu, Yunhong , Selwyn, Reed , Hart, Blaine L. , Feghali, James , Sair, Haris I. , Narvid, Jared , Lupo, Janine , Stadnik, Agnieszka , Hobson, Nicholas , DeBiasse, Dorothy , Lane, Karen , McBee, Nichole, Treine, Kevin, Ostapkovich, Noeleen , Wang, Ying, Thompson, Richard E. , Awad, Issam A. , Huston, John , Flemming, Kelly D , Kim, Helen , Torbey, Michel , Huang, Judy , Shu, Yunhong , Selwyn, Reed , Feghali, James , Narvid, Jared , Alcazar-Felix, Roberto J , Shenkar, Robert , Hobson, Nicholas , DeBiasse, Dorothy , Lane, Karen , Ostapkovich, Noeleen , Koenig, James I , Carroll, Timothy , Hanley, Daniel F , Awad, Issam , Girard, Romuald , Mabray, Marc C. , Lee, Justine C. , Alcazar‐Félix, Roberto J. , Shenkar, Robert , Koenig, James I. , Hanley, Daniel F.

Mayo Clinic

Stroke | December 22, 2023 | Volume: 55 | Issue: 1 | Pages: 31-39

10.1161/strokeaha.123.044083 | PMID 38134265 Get It

BACKGROUND: Quantitative susceptibility mapping (QSM) and dynamic contrast-enhanced quantitative perfusion (DCEQP) magnetic resonance imaging sequences assessing iron deposition and vascular permeability were previously correlated with new hemorrhage in cerebral cavernous malformations. We assessed their prospective changes in a multisite trial-readiness project. METHODS: Patients with cavernous malformation and symptomatic hemorrhage (SH) in the prior year, without prior or planned lesion resection or irradiation were enrolled. Mean QSM and DCEQP of the SH lesion were acquired at baseline and at 1- and 2-year follow-ups. Sensitivity and specificity of biomarker changes were analyzed in relation to predefined criteria for recurrent SH or asymptomatic change. Sample size calculations for hypothesized therapeutic effects were conducted. RESULTS: We logged 143 QSM and 130 DCEQP paired annual assessments. Annual QSM change was greater in cases with SH than in cases without SH ( P =0.019). Annual QSM increase by ≥6% occurred in 7 of 7 cases (100%) with recurrent SH and in 7 of 10 cases (70%) with asymptomatic change during the same epoch and 3.82× more frequently than clinical events. DCEQP change had lower sensitivity for SH and asymptomatic change than QSM change and greater variance. A trial with the smallest sample size would detect a 30% difference in QSM annual change during 2 years of follow-up in 34 or 42 subjects (1 and 2 tailed, respectively); power, 0.8, α=0.05. CONCLUSIONS: Assessment of QSM change is feasible and sensitive to recurrent bleeding in cavernous malformations. Evaluation of an intervention on QSM percent change may be used as a time-averaged difference between 2 arms using a repeated measures analysis. DCEQP change is associated with lesser sensitivity and higher variability than QSM. These results are the basis of an application for certification by the US Food and Drug Administration of QSM as a biomarker of drug effect on bleeding in cavernous malformations. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03652181.
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome
Flemming, Kelly D. , Kim, Helen , Hage, Stephanie , Mandrekar, Jay , Kinkade, Serena , Torbey, Michel , Huang, Judy , Huston, John , Shu, Yunhong , Selwyn, Reed , Hart, Blaine L. , Feghali, James , Sair, Haris I. , Narvid, Jared , Lupo, Janine , Stadnik, Agnieszka , Lane, Karen , McBee, Nichole, Treine, Kevin, Ostapkovich, Noeleen , Wang, Ying , Thompson, Richard E. , Awad, Issam A. , Huston, John , Torbey, Michel , Huang, Judy , Shu, Yunhong , Lanzino, Giuseppe , Selwyn, Reed , Hart, Blaine , Mabray, Marc C , Feghali, James , Narvid, Jared , Alcazar-Felix, Roberto J , Shenkar, Robert , Lane, Karen , Ostapkovich, Noeleen , Koenig, James I , Carroll, Timothy , Hanley, Daniel F , Awad, Issam , Flemming, Kelly D , Kim, Helen , Girard, Romuald , Lanzino, Giuseppe , Mabray, Marc C. , Lee, Justine C. , Alcazar‐Félix, Roberto J. , Shenkar, Robert , Koenig, James I. , Hanley, Daniel F.

Mayo Clinic

Stroke | December 22, 2023 | Volume: 55 | Issue: 1 | Pages: 22-30

10.1161/strokeaha.123.044068 | PMID 38134268 Get It

BACKGROUND: Cerebral cavernous malformation with symptomatic hemorrhage (SH) are targets for novel therapies. A multisite trial-readiness project ( https://www.clinicaltrials.gov ; Unique identifier: NCT03652181) aimed to identify clinical, imaging, and functional changes in these patients. METHODS: We enrolled adult cerebral cavernous malformation patients from 5 high-volume centers with SH within the prior year and no planned surgery. In addition to clinical and imaging review, we assessed baseline, 1- and 2-year National Institutes of Health Stroke Scale, modified Rankin Scale, European Quality of Life 5D-3 L, and patient-reported outcome-measurement information system, Version 2.0. SH and asymptomatic change rates were adjudicated. Changes in functional scores were assessed as a marker for hemorrhage. RESULTS: One hundred twenty-three, 102, and 69 patients completed baseline, 1- and 2-year clinical assessments, respectively. There were 21 SH during 178.3 patient years of follow-up (11.8% per patient year). At baseline, 62.6% and 95.1% of patients had a modified Rankin Scale score of 1 and National Institutes of Health Stroke Scale score of 0 to 4, respectively, which improved to 75.4% ( P =0.03) and 100% ( P =0.06) at 2 years. At baseline, 74.8% had at least one abnormal patient-reported outcome-measurement information system, Version 2.0 domain compared with 61.2% at 2 years ( P =0.004). The most common abnormal European Quality of Life 5D-3 L domains were pain (48.7%), anxiety (41.5%), and participation in usual activities (41.4%). Patients with prospective SH were more likely than those without SH to display functional decline in sleep, fatigue, and social function patient-reported outcome-measurement information system, Version 2.0 domains at 2 years. Other score changes did not differ significantly between groups at 2 years. The sensitivity of scores as an SH marker remained poor at the time interval assessed. CONCLUSIONS: We report SH rate, functional, and patient-reported outcomes in trial-eligible cerebral cavernous malformation with SH patients. Functional outcomes and patient-reported outcomes generally improved over 2 years. No score change was highly sensitive or specific for SH and could not be used as a primary end point in a trial.
A Novel Acetone Sensor for Body Fluids
Pérez, Óscar Osorio , Nguyen, Ngan Anh, Hendricks, Asher, Victor, Shaun , Yu, Nanxi , Xian, Xiaojun , Kulick, Doina , Forzani, Erica , Xian, Xiaojun , Wang, Shaopeng , Perez, Oscar Osorio, Mora, Sabrina , Wang, Shaopeng

Mayo Clinic

Biosensors | December 22, 2023 | Volume: 14 | Issue: 1 | Pages: 4

10.3390/bios14010004 | PMID 38248381 Get It

Ketones are well-known biomarkers of fat oxidation produced in the liver as a result of lipolysis. These biomarkers include acetoacetic acid and β-hydroxybutyric acid in the blood/urine and acetone in our breath and skin. Monitoring ketone production in the body is essential for people who use caloric intake deficit to reduce body weight or use ketogenic diets for wellness or therapeutic treatments. Current methods to monitor ketones include urine dipsticks, capillary blood monitors, and breath analyzers. However, these existing methods have certain disadvantages that preclude them from being used more widely. In this work, we introduce a novel acetone sensor device that can detect acetone levels in breath and overcome the drawbacks of existing sensing approaches. The critical element of the device is a robust sensor with the capability to measure acetone using a complementary metal oxide semiconductor (CMOS) chip and convenient data analysis from a red, green, and blue deconvolution imaging approach. The acetone sensor device demonstrated sensitivity of detection in the micromolar-concentration range, selectivity for detection of acetone in breath, and a lifetime stability of at least one month. The sensor device utility was probed with real tests on breath samples using an established blood ketone reference method.
Screening Performance of S100 Calcium-Binding Protein B, Glial Fibrillary Acidic Protein, and Ubiquitin C-Terminal Hydrolase L1 for Intracranial Injury Within Six Hours of Injury and Beyond
Trivedi, Dhanisha , Forssten, Maximilian Peter , Czeiter, Endre , Amrein, Krisztina , Büki, András , DeSoucy, Erik, Cao, Yang , Ismail, Ahmad Mohammad , Kobeissy, Firas , Wang, Kevin , DeSoucy, Erik S. , Mohseni, Shahin

Mayo Clinic

Journal of Neurotrauma | December 20, 2023 | Volume: 41 | Issue: 3-4 | Pages: 349-358

10.1089/neu.2023.0322 | PMID 38115670 Get It

Abstract 17216: Limited Concordance of Core Lab Left Ventricular Ejection Fraction With Automated Assessments: A Sub-Study From VALOR-HCM
Parizher, Gary , Owens, Anjali , Wolski, Kathy , Geske, Jeffrey B. , Lakdawala, Neal K. , Naidu, Srihari S. , Smedira, Nicholas G. , McErlean, Ellen, Sewell, Christina , Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Desai, Milind Y. , Cremer, Paul , Geske, Jeffrey B , Cremer, Paul C , Jaber, Wael A. , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fifer, Michael A. , Fermin, David , Schaff, Hartzell V.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.17216 Get It

Introduction: The performance of automated left ventricular ejection fraction (LVEF) assessment in patients with altered cardiac chamber geometry, such as those with obstructive hypertrophic cardiomyopathy (HCM), is not well described. Aims: Accurate assessment of LVEF is required for dose titration and continuation of myosin inhibitors in obstructive HCM. From the VALOR-HCM trial (NCT04349072), the agreement of two commercially available software packages was compared with blinded core lab assessment of LVEF. Methods: From baseline and week 16, among 112 patients randomized to either mavacamten or placebo, 178 echocardiograms were analyzed. Representative clips were manually selected, and automated LVEFs were calculated. Comparisons of LVEFs were made using Pearson’s correlation coefficients and Bland-Altman analysis. Results: With core lab assessment, the overall median LVEF was 68% (Q1 66%, Q3 70%). The correlation with vendor 1 was moderate (r = 0.47, 95% CI 0.35-0.58, p <0.001) and weak with vendor 2 (r =0.21, 95% CI 0.07-0.35, p =0.004). Correlation was also weak between vendor 1 and 2 (r = 0.14, 95% CI 0.00-0.28, p = 0.06). Vendors 1 and 2 had an underestimation bias of LVEF of 8% (95% CI 6-9%) and 8% (95% CI 7-9%), respectively, compared to core lab LVEF (Figure 1). Conclusions: In VALOR-HCM, the concordance of LVEF between different commercially available software packages with each other and with a core lab assessment was limited. Further study is needed to evaluate and improve the performance of automated LVEF tools in obstructive HCM patients who have altered cardiac chamber geometry.
Abstract 16898: Myocardial Recovery Associated Gene Cdcp1 Expression Attenuates Cardiac Fibrosis in a Pressure Over-Load Mouse Model
Wang, Min , Vyas, Hridyanshu , Roos, Carolyn M, Huang, Runqing, Sahni, Jyotan , McNamara, Dennis M. , Barlera, Simona, Merlo, Marco , Chaloupka, Anna , Krejčí, Jan , Weinshilboum, Richard M. , Pereira, Naveen L. , Liu, Duan , Pileggi, Silvana , Mestroni, Luisa , Sinagra, Gianfranco , Pinet, F , Groote, Pascal de , Weinshilboum, Richard M. , Miller, Jordan D.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16898 Get It

Background: We have previously demonstrated by performing a genome-wide association study that a genetic locus resulting in ↓CDCP1 expression was associated with myocardial recovery in patients with dilated cardiomyopathy (DCM). We have subsequently shown that ↓CDCP1 decreases human cardiac fibroblast proliferation in vitro , however, its potential role in modulating cardiac fibrosis and function in vivo is unknown. Methods: A Cdcp1 knock-out (KO) mouse was generated on FVB/NJ background. Angiotensin II/Phenylephrine (AngII/PE) or saline was infused by an osmotic pump into mice ( Cdcp1 KO n=20; wild type/wt n=18) for 4 weeks. Echocardiography was performed at 0 and 4 weeks. Picrosirius red (PSR) staining was performed on cross-sectional heart tissue to identify cardiac fibrosis, which was quantified, using ImageJ software, as a percentage of left ventricular (LV) area stained by PSR. Results: LV mass index (LVMI) significantly increased in AngII/PE wt mice as compared to saline wt (figure a. 3.65±0.15 mg/g vs 3.05±0.17mg/g, p=0.01), however, AngII/PE Cdcp1 KO mice had significantly decreased LVMI as compared to AngII/PE wt mice (figure a. 3.17±0.09 mg/g vs 3.65±0.15 mg/g, p=0.01). In addition, fractional shortening trended higher in AngII/PE Cdcp1 KO mice as compared to AngII/PE wt mice (figure b. 50.36±2.06% vs 45.48±1.43%, p=0.07). Extent of cardiac fibrosis was significantly higher in AngII/PE wt mice as compared to saline wt (figure c. 15.79±0.49% vs 7.93±0.39%, p<0.0001), however AngII/PE Cdcp1 KO mice had significantly reduced cardiac fibrosis as compared to AngII/PE wt mice (figure c. 9.41±0.43%, p<0.0001). Conclusions: CDCP1 KO significantly reduces pressure over-load induced LV hypertrophy and cardiac fibrosis. Its role as a novel therapeutic target in attenuating fibrosis and improving cardiac function in DCM needs to be further explored.